Obligatory role for endothelial heparan sulphate proteoglycans and caveolae internalization in catestatin-dependent eNOS activation

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Fornero, Sara ^a   Bassino, Eleonora ^a   Ramella, Roberta ^a   Gallina, Clara ^a   Mahata, Sushil K ^b,c   Tota, Bruno ^d,e   Levi, Renzo ^a   Alloatti, Giuseppe ^a,e   Gallo, Maria Pia ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALABRIA   (Italy)

^e National Institute for Cardiovascular Research   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CATESTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEPARIN LYASE; METHYL BETA CYCLODEXTRIN; PROTEOHEPARAN SULFATE; WORTMANNIN; CAVEOLIN 1; CHROMOGRANIN A; CHROMOGRANIN A (344-364); NITRIC OXIDE; PEPTIDE FRAGMENT;

ANIMAL CELL; AORTA ENDOTHELIUM; ARTICLE; CAVEOLA; CELL TRANSPORT; CONTROLLED STUDY; ENDOCYTOSIS; ENDOTHELIUM CELL; ENZYME ACTIVATION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; INTERNALIZATION; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; ANIMAL; AORTA; BOVINE; DRUG EFFECTS; METABOLISM; TRANSPORT VESICLE; ULTRASTRUCTURE;

ANIMALS; AORTA; CATTLE; CAVEOLAE; CAVEOLIN 1; CHROMOGRANIN A; ENDOCYTOSIS; ENDOTHELIAL CELLS; HEPARAN SULFATE PROTEOGLYCANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDE FRAGMENTS; TRANSPORT VESICLES;

EID: 84929050828     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/783623     Document Type: Article

References (45)

1. K. B. Helle, A. Corti, M.-H. Metz-Boutigue, and B. Tota, "The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties, " Cellular andMolecular Life Sciences, vol. 64, no. 22, pp. 2863-2886, 2007.
2. B. Tota, M. C. Cerra, and A. Gattuso, "Catecholamines, cardiac natriuretic peptides and chromogranin A: evolution and physiopathology of a "whip-brake" system of the endocrine heart, " Journal of Experimental Biology, vol. 213, no. 18, pp. 3081-3103, 2010.
3. A. Bartolomucci, R. Possenti, S. K. Mahata, R. Fischer-Colbrie, Y. P. Loh, and S. R. J. Salton, "The extended granin family: structure, function, and biomedical implications, " Endocrine Reviews, vol. 32, no. 6, pp. 755-797, 2011.
4. M. Pieroni, A. Corti, B. Tota et al. , "Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function, " European Heart Journal, vol. 28, no. 9, pp. 1117-1127, 2007.
5. S. K. Mahata, D. T. OConnor, M. Mahata et al. , "Novel autocrine feedback control of catecholamine release: a discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist, " Journal of Clinical Investigation, vol. 100, no. 6, pp. 1623-1633, 1997.
6. T. Angelone, A. M. Quintieri, B. K. Brar et al. , "The antihypertensive chromogranin A peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropismand lusitropism, " Endocrinology, vol. 149, no. 10, pp. 4780-4793, 2008.
7. S. K. Mahata, M. Mahata, M. M. Fung, and D. T. OConnor, "Catestatin: a multifunctional peptide from chromogranin A, " Regulatory Peptides, vol. 162, no. 1-3, pp. 33-43, 2010.
8. S. K. Mahata, M. Mahata, R. J. Parmer, and D. T. OConnor, "Desensitization of catecholamine release: the novel catecholamine release-inhibitory peptide catestatin (chromogranin A344-364) acts at the receptor to prevent nicotinic cholinergic tolerance, "The Journal of Biological Chemistry, vol. 274, no. 5, pp. 2920-2928, 1999.
9. B. P. Kennedy, S. K. Mahata, D. T. OConnor, and M. G. Ziegler, "Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo, " Peptides, vol. 19, no. 7, pp. 1241-1248, 1998.
10. P. Kruger, S. K. Mahata, and K. B. Helle, "Catestatin (CgA344-364) stimulates rat mast cell release of histamine in a manner comparable to mastoparan and other cationic charged neuropeptides, " Regulatory Peptides, vol. 114, no. 1, pp. 29-35, 2003.
11. A. H. Gaede and P. M. Pilowsky, "Catestatin, a chromogranin A-derived peptide, is sympathoinhibitory and attenuates sympathetic barosensitivity and the chemoreflex in rat CVLM, " American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 302, no. 3, pp. R365-R372, 2012.
12. D. T. OConnor, M. T. Kailasam, B. P. Kennedy, M. G. Ziegler, N. Yanaihara, and R. J. Parmer, "Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension, " Journal of Hypertension, vol. 20, no. 7, pp. 1335-1345, 2002.
13. L. Liu, W. Ding, R. Li et al. , "Plasma levels and diagnostic value of catestatin in patients with heart failure, " Peptides, vol. 46, pp. 20-25, 2013.
14. L. Liu, W. Ding, F. Zhao, L. Shi, Y. Pang, and C. Tang, "Plasma levels and potential roles of catestatin in patients with coronary heart disease, " Scandinavian Cardiovascular Journal, vol. 47, no. 4, pp. 217-224, 2013.
15. N. R. Mahapatra, D. T. OConnor, S. M. Vaingankar et al. , "Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog, " Journal of Clinical Investigation, vol. 115, no. 7, pp. 1942-1952, 2005.
16. J. R. Gayen, Y. Gu, D. T. OConnor, and S. K. Mahata, "Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin A null mouse, " Endocrinology, vol. 150, no. 11, pp. 5027-5035, 2009.
17. N. B. Dev, J. R. Gayen, D. T. OConnor, and S. K. Mahata, "Chromogranin A and the autonomic system: decomposition of heart rate variability and rescue by its catestatin fragment, " Endocrinology, vol. 151, no. 6, pp. 2760-2768, 2010.
18. E. Bassino, S. Fornero, M. P. Gallo et al. , "A novel catestatininduced antiadrenergic mechanism triggered by the endothelial PI3KeNOS pathway in the myocardium, " Cardiovascular Research, vol. 91, no. 4, pp. 617-624, 2011.
19. M. Sugawara, J. M. Resende, C. M. Moraes et al. , "Membrane structure and interactions of human catestatin by multidimensional solution and solid-state NMR spectroscopy, " The FASEB Journal, vol. 24, no. 6, pp. 1737-1746, 2010.
20. K. A. Radek, B. Lopez-Garcia, M. Hupe et al. , "The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury, " Journal of Investigative Dermatology, vol. 128, no. 6, pp. 1525-1534, 2008.
21. J. Briolat, S. D. Wu, S. K. Mahata et al. , "New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A, " Cellular and Molecular Life Sciences, vol. 62, no. 3, pp. 377-385, 2005.
22. R. Ramella, O. Boero, G. Alloatti, T. Angelone, R. Levi, and M. P. Gallo, "Vasostatin 1 activates eNOS in endothelial cells through a proteoglycan-dependent mechanism, " Journal of Cellular Biochemistry, vol. 110, no. 1, pp. 70-79, 2010.
23. S. Fornero, E. Bassino, M. P. Gallo, R. Ramella, R. Levi, and G. Alloatti, "Endothelium dependent cardiovascular effects of the chromogranin a-derived peptides vasostatin-1 and catestatin, " Current Medicinal Chemistry, vol. 19, no. 24, pp. 4059-4067, 2012.
24. S. K. Mahata, M. Mahata, A. R. Wakade, and D. T. OConnor, "Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A344-364): identification of amino acid residues crucial for activity, " Molecular Endocrinology, vol. 14, no. 10, pp. 1525-1535, 2000.
25. W. D. Niles and A. B. Malik, "Endocytosis and exocytosis events regulate vesicle traffic in endothelial cells, " Journal ofMembrane Biology, vol. 167, no. 1, pp. 85-101, 1999.
26. M. C. Morris, S. Deshayes, F. Heitz, and G. Divita, "Cellpenetrating peptides: frommolecularmechanisms to therapeutics, " Biology of the Cell, vol. 100, no. 4, pp. 201-217, 2008.
27. N. A. Maniatis, V. Brovkovych, S. E. Allen et al. , "Novel mechanism of endothelial nitric oxide synthase activation mediated by caveolae internalization in endothelial cells, " Circulation Research, vol. 99, no. 8, pp. 870-877, 2006.
28. F. A. Sanchez, D. D. Kim, R. G. Duŕan, C. J. Meininger, and W. N. Duŕan, "Internalization of eNOS via caveolae regulates PAFinduced inflammatory hyperpermeability to macromolecules, " The American Journal of Physiology: Heart and Circulatory Physiology, vol. 295, no. 4, pp. H1642-H1648, 2008.
29. R. D. Minshall, W. C. Sessa, R. V. Stan, R. G. W. Anderson, and A. B. Malik, "Caveolin regulation of endothelial function, " American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 285, no. 6, pp. L1179-L1183, 2003.
30. A. T. Jones and E. J. Sayers, "Cell entry of cell penetrating peptides: tales of tails wagging dogs, " Journal of Controlled Release, vol. 161, no. 2, pp. 582-591, 2012.
31. D. Zhang, P. Shooshtarizadeh, B. Laventie et al. , "Two chromogranin a-derived peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium independent phospholipase A2, " PLoS ONE, vol. 4, no. 2, Article ID e4501, 2009.
32. M. M. Fretz, N. A. Penning, S. Al-Taei et al. , "Temperature-, concentration-and cholesterol-dependent translocation of Land D-octa-arginine across the plasma and nuclear membrane of CD34+ leukaemia cells, " Biochemical Journal, vol. 403, no. 2, pp. 335-342, 2007.
33. D. L. Rabenstein, "Heparin and heparan sulfate: structure and function, " Natural Product Reports, vol. 19, no. 3, pp. 312-331, 2002.
34. M. Belting, "Heparan sulfate proteoglycan as a plasma membrane carrier, " Trends in Biochemical Sciences, vol. 28, no. 3, pp. 145-151, 2003.
35. J. M. Tarbell, "Shear stress and the endothelial transport barrier, " Cardiovascular Research, vol. 87, no. 2, pp. 320-330, 2010.
36. I. Fleming, "Molecular mechanisms underlying the activation of eNOS, " Pflugers Archiv European Journal of Physiology, vol. 459, no. 6, pp. 793-806, 2010.
37. S. V. Lopez-Quintero, R. Amaya, M. Pahakis, and J. M. Tarbell, "The endothelial glycocalyx mediates shear-induced changes inhydraulic conductivity, " The American Journal of Physiology-Heart and Circulatory Physiology, vol. 296, no. 5, pp. H1451-H1456, 2009.
38. P. Mellor, L. A. Furber, J. N. K. Nyarko, and D. H. Anderson, "Multiple roles for the p85α isoformin the regulation and function of PI3K signalling and receptor trafficking, " Biochemical Journal, vol. 441, no. 1, pp. 23-37, 2012.
39. R. Aslam, M. Atindehou, T. Lavaux, Y. Häkel, F. Schneider, and M.-H. Metz-Boutigue, "Chromogranin a-derived peptides are involved in innate immunity, " CurrentMedicinal Chemistry, vol. 19, no. 24, pp. 4115-4123, 2012.
40. G. Aung, F. Niyonsaba, H. Ushio et al. , "Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokines, " Immunology, vol. 132, no. 4, pp. 527-539, 2011.
41. K. B. Helle, "Regulatory peptides from chromogranin A and secretogranin II: putative modulators of cells and tissues involved in inflammatory conditions, " Regulatory Peptides, vol. 165, no. 1, pp. 45-51, 2010.
42. K. B. Helle, "The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions, " Cardiovascular Research, vol. 85, no. 1, pp. 9-16, 2010.
43. K. B. Helle, "Chromogranins A and B and secretogranin II as prohormones for regulatory peptides fromthe diffuse neuroendocrine system, " Results and Problems in Cell Differentiation, vol. 50, pp. 21-44, 2010.
44. N. R. Mahapatra, "Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure, " Cardiovascular Research, vol. 80, no. 3, pp. 330-338, 2008.
45. G. K. Bandyopadhyay, C. U. Vu, S. Gentile et al. , "Catestatin (Chromogranin A352?372) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling, " Journal of Biological Chemistry, vol. 287, no. 27, pp. 23141-23151, 2012.